Stock TNGX TANGO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
7.44 USD +1.50% Intraday chart for Tango Therapeutics, Inc. +1.78% -24.85%
04-04 British billionaire Joe Lewis fined $5 million by US judge for insider trading RE
04-04 Multibillionaire Joe Lewis to face US sentencing for insider trading RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
British billionaire Joe Lewis fined $5 million by US judge for insider trading
RE
Multibillionaire Joe Lewis to face US sentencing for insider trading
RE
Cantor Fitzgerald Initiates Coverage on Tango Therapeutics With Overweight Rating
MT
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
H.C. Wainwright Adjusts Price Target on Tango Therapeutics to $17 From $16, Keeps Buy Rating
MT
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M
MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
BU
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index
CI
Transcript : Tango Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM
Tango Therapeutics to Participate in Upcoming Investor Conferences
BU
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
AQ
Piper Sandler Initiates Tango Therapeutics With Overweight Rating
MT
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
AQ
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says
RE
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
PR
Medivir's licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study
AQ
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNGX Stock
  4. News Tango Therapeutics, Inc.